文献速递免疫规划卫生政策与健康促进

新兴制造商参与COVID-19疫苗研发与供应

Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply.
PubMed 文献 · Vaccine · 2020-06-11

通过在线检索、网络成员直接沟通和内部调查,评估发展中国家疫苗制造商网络成员参与COVID-19疫苗研发及生产、灌装和分发的能力。目前19个网络成员参与COVID-19疫苗研发,使用六种主要技术平台;利用现有生产、灌装和分发能力可支持COVID-19疫苗的有效推出,同时维持现有免疫规划疫苗的供应安全。

要点

  • 19个网络成员参与COVID-19疫苗研发,使用六种主要技术平台。
  • 近三分之一网络成员有WHO预认证疫苗,符合国际法规和跨境分发机制。

核心结论

  • 利用现有生产、灌装和分发能力可支持COVID-19疫苗的有效推出,同时维持现有免疫规划疫苗的供应安全。

研究设计与样本

  • 通过在线检索、与网络成员直接沟通及内部调查,评估发展中国家疫苗制造商网络成员参与COVID-19疫苗研发及生产、灌装和分发的能力。

主要发现

  • 目前19个网络成员参与COVID-19疫苗研发,使用六种主要技术平台。
  • 近三分之一网络成员有WHO预认证疫苗,符合国际法规和跨境分发机制。

临床怎么用

  • 可依托现有生产、灌装和分发能力支持COVID-19疫苗推出,并维持现有免疫规划疫苗供应安全。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The World Health Organization declared the COVID-19 disease as a pandemic requiring a rapid response. Through online search, direct communication with network members and an internal survey, engagements of developing countries' vaccine manufacturers' network members in the research and development of COVID-19 vaccines and their capacities in the manufacturing, fill-finish and distribution of vaccines were assessed. Currently, 19 network members engaged in research and development of COVID-19 vaccines, using six principal technology platforms. In addition, an internal survey showed that the number of vaccines supplied collectively by 37 members, in 2018-19, was about 3.5 billion doses annually. Almost a third of network members having vaccines prequalified by the World Health Organization comply with international regulations and mechanisms to distribute vaccines across borders. The use of existing manufacturing, fill-finish and distribution capabilities can support an efficient roll-out of vaccines against COVID-19, while maintaining supply security of existing vaccines for on-going immunization programmes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Pagliusi S, Jarrett S, Hayman B, et al. Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply. Vaccine. 2020. PMID: 32600908. doi:10.1016/j.vaccine.2020.06.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。